SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Illumina (ILMN) Optics for Genomics
ILMN 119.99-2.9%Nov 3 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: mopgcw4/7/2006 11:06:44 AM
   of 276
 
Illumina Up; Co. Sees 1Q Results Topping Forecast -2
10:56 AM EDT April 7, 2006

Illumina competitor Affymetrix recently lowered the prices of its highest density genotyping array, which Leerink Swann analyst John L. Sullivan believes is in response to customer adoption of Illumina's genotyping products.
"We believe Illumina offers a compelling and cost-effective approach to high-density gene expression analysis," Sullivan said.
Sullivan said recent conversations with MEDAcorp consultants have indicated that Illumina's BeadChip arrays are both "compelling and differentiated" as Affymetrix seeks to improve upon its own high-density genotyping products.
Sullivan, who had Illumina at outperform Friday, said Illumina's is well-positioned in the attractive high-density genotyping market and share is available for Illumina's additive new technologies.
"Illumina's BeadArray products must be priced within the context of the market given their unique capability and availability," Sullivan later added. "We expect Illumina's products to be especially compelling to disease-state researchers seeking casual variants within genes."
The analyst reiterated his outperform rating on the stock, citing Illumina's "attractive" valuation.
Neither Sullivan nor Tenthoff own shares in the company, but Leerink Swann and Piper Jaffray both make markets in Affymetrix and Illumina.
-By Nicole Urbanowicz, Dow Jones Newswires; 201-938-5460; nicole.urbanowicz@dowjones.com

(END) Dow Jones Newswires
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News